Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]
F1000Research, 2022 Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.
Samantha E. Jacobs +2 more
doaj +1 more source
Fungal cell wall : An underexploited target for antifungal therapies [PDF]
, 2021 Funding: The authors would like to acknowledge support from the University of Aberdeen and Abia State University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Peer ...
Ibe, Chibuike, Munro, Carol
core +1 more source
Current management and new horizons in the treatment of oral candidiasis [PDF]
, 2023 Introduction: this study evaluated the effectiveness and perceptions of current treatments for oral candidiasis among dentists in the Salcedo canton.
Culqui Molina, Washington Paúl +3 more
core +2 more sources
Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia [PDF]
Biology of Blood and Marrow Transplantation, 2019 Background The risk of Pneumocystis pneumonia often warrants antifungal prophylaxis for bone marrow and solid organ transplantation patients. However, complications such as myelosuppression, nephrotoxicity, and intolerance with the existing standard, TMP/SMX, may hinder or interrupt prophylaxis. Rezafungin (RZF) is a novel echinocandin in development
Melanie Cushion, Alan Ashbaugh
openaire +1 more source
Metabolism, Excretion, and Mass Balance of [ 14 C]-Rezafungin in Animals and Humans
Antimicrobial Agents and Chemotherapy, 2022 Rezafungin is a novel echinocandin being developed for treatment of candidemia and invasive candidiasis and for prevention of invasive fungal disease caused by Candida, Aspergillus , and Pneumocystis spp. in recipients of blood and marrow transplantation. Studies using [
Voon Ong +4 more
openaire +2 more sources
Journal of Fungi, 2022 Several new antifungals are currently in late-stage development, including those with novel pharmacodynamics/mechanisms of action that represent new antifungal classes (manogepix, olorofim, ATI-2307, GR-2397). Others include new agents within established
Nathan P. Wiederhold
doaj +1 more source
Successful rezafungin treatment of an azole-resistant Candida parapsilosis vascular graft infection. [PDF]
Rev Esp QuimioterBenítez-Cano A +7 more
europepmc +3 more sources
Advances in the Treatment of Invasive Fungal Disease [PDF]
, 2023 With over 300 million severe cases and 1.5 million deaths annually, invasive fungal diseases (IFDs) are a major medical burden and source of global morbidity and mortality.
An, Zhiqiang +2 more
core +1 more source
IDCasesIntroduction: Invasive candidiasis is a common healthcare-associated infection with significant morbidity and mortality. Candida auris in particular has emerged as a problematic and challenging healthcare-associated infection, especially with regards to ...
Matthew A. Stack +5 more
doaj +1 more source
Incidence of Pneumocystis pneumonia in immunocompromised patients without human immunodeficiency virus on intravenous pentamidine prophylaxis: A systematic review and meta-analysis [PDF]
, 2023 BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is a first-line METHOD: We performed a systematic review and meta-analysis to estimate breakthrough PCP incidence and adverse reactions in HIV-uninfected immunocompromised patients receiving IVP ...
Ching, Patrick R, Chiu, Chia-Yu
core +2 more sources